Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IAG933

Phase 1Small molecule

IAG933 is one of 20 small molecule programs targeting Mesothelioma. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

19

Competitors

Pipeline

Status by Indication[3][1]

Indication

MesotheliomaActive, not recruiting

MesotheliomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Mesothelioma

#DrugCompanyPhaseTrials

Iressa

Afinitor

Lynparza

Zometa

Nexavar

Mitosol

UUroGen Pharma Ltd.

Yondelis

Epsom Salt

FFresenius Kabi USA, LLC

Tazverik

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Mesothelioma

NCT04857372

Clinical

Trials by Indication[1]

Mesothelioma1 trial

An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT04857372·137 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IAG933. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IAG933 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IAG933. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novartis

Related News